RUBIUS THERAPEUTICS INC (RUBY) Stock Fundamental Analysis

NASDAQ:RUBY • US78116T1034

0.083 USD
-0.04 (-33.55%)
At close: Mar 6, 2023
0.0899 USD
+0.01 (+8.31%)
After Hours: 3/6/2023, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RUBY. RUBY was compared to 521 industry peers in the Biotechnology industry. While RUBY seems to be doing ok healthwise, there are quite some concerns on its profitability. RUBY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • RUBY had negative earnings in the past year.
  • In the past year RUBY has reported a negative cash flow from operations.
RUBY Yearly Net Income VS EBIT VS OCF VS FCFRUBY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • The profitability ratios for RUBY are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RUBY Yearly ROA, ROE, ROICRUBY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800 -1K

1.3 Margins

  • RUBY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RUBY Yearly Profit, Operating, Gross MarginsRUBY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • RUBY has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for RUBY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RUBY Yearly Shares OutstandingRUBY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
RUBY Yearly Total Debt VS Total AssetsRUBY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

  • RUBY has an Altman-Z score of -68.99. This is a bad value and indicates that RUBY is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of RUBY (-68.99) is worse than 93.08% of its industry peers.
  • RUBY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -68.99
ROIC/WACCN/A
WACCN/A
RUBY Yearly LT Debt VS Equity VS FCFRUBY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

  • RUBY has a Current Ratio of 2.54. This indicates that RUBY is financially healthy and has no problem in meeting its short term obligations.
  • RUBY's Current ratio of 2.54 is on the low side compared to the rest of the industry. RUBY is outperformed by 75.31% of its industry peers.
  • A Quick Ratio of 2.54 indicates that RUBY has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.54, RUBY is not doing good in the industry: 74.53% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.54
RUBY Yearly Current Assets VS Current LiabilitesRUBY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 10.65% over the past year.
EPS 1Y (TTM)10.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y64.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RUBY Yearly EPS VS EstimatesRUBY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • RUBY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RUBY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RUBY Price Earnings VS Forward Price EarningsRUBY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RUBY Per share dataRUBY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RUBY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RUBIUS THERAPEUTICS INC

NASDAQ:RUBY (3/6/2023, 8:00:03 PM)

After market: 0.0899 +0.01 (+8.31%)

0.083

-0.04 (-33.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners7.7%
Ins Owner Change0%
Market Cap7.50M
Revenue(TTM)N/A
Net Income(TTM)-179.67M
Analysts45.71
Price Target1.02 (1128.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.72%
Min EPS beat(2)8.72%
Max EPS beat(2)8.72%
EPS beat(4)3
Avg EPS beat(4)6.89%
Min EPS beat(4)2.24%
Max EPS beat(4)9.7%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-90.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-1.99
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.81%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.54
Altman-Z -68.99
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)76.24%
Cap/Depr(5y)554.11%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.54%
EPS Next Y64.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.46%
OCF growth 3YN/A
OCF growth 5YN/A

RUBIUS THERAPEUTICS INC / RUBY FAQ

What is the ChartMill fundamental rating of RUBIUS THERAPEUTICS INC (RUBY) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RUBY.


Can you provide the valuation status for RUBIUS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 3 / 10 to RUBIUS THERAPEUTICS INC (RUBY). This can be considered as Overvalued.


How profitable is RUBIUS THERAPEUTICS INC (RUBY) stock?

RUBIUS THERAPEUTICS INC (RUBY) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for RUBY stock?

The Earnings per Share (EPS) of RUBIUS THERAPEUTICS INC (RUBY) is expected to grow by 64.38% in the next year.